|Bid||14.52 x 800|
|Ask||14.74 x 1100|
|Day's range||14.54 - 14.77|
|52-week range||3.36 - 24.34|
|Beta (5Y monthly)||1.72|
|PE ratio (TTM)||39.38|
|Earnings date||09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||26.25|
Organogenesis (ORGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: Xencor, Organogenesis Holdings, Cumberland Pharmaceuticals and Acer Therapeutics
Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.